The UK Stem Cell Therapy Market was valued at $0.4 Million in 2026 and projected to reach to $136.8 Million by 2031, representing a compound annual growth rate of 0.0%. The UK stem cell therapy market stands at a transformative juncture, transitioning from early-stage research to mainstream clinical application.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The UK stem cell therapy market is experiencing unprecedented expansion, growing from $0.4 million in 2026 to $136.8 million by 2031, representing a 34,600% increase over five years and significantly outpacing the global CAGR of 25.3%.
The UK's strengthened regulatory environment post-Brexit has created a competitive advantage, with the MHRA establishing clearer pathways for stem cell therapy approval and accelerating clinical trial approvals compared to previous years.
Increased government funding through UK Research and Innovation (UKRI) and private sector investment in regenerative medicine research hubs across London, Cambridge, and Oxford is driving innovation and commercialization of stem cell therapies.
NHS integration of stem cell-based treatments for conditions including orthopedic disorders, cardiovascular disease, and neurological conditions is accelerating, with multiple therapies moving through clinical validation stages in UK healthcare institutions.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | ALLOGENEIC STEM CELL THERAPY (Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 25.3% from 2026 to 2031 |
| Largest Segment | ALLOGENEIC STEM CELL THERAPY (Type) |
| Market Size Base Year (Billions) | ~USD 0.48 (2026) |
| Revenue Forecast (Billions) | ~USD 1.48 (2031) |
| Segments Covered | Type, Therapeutic Application, Cell Source |
3 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| KINDRED HEALTHCARE INC. | United States | Private Company | Long-term acute care hospitals (LTACH) – drug-intensive episodes,Inpatient rehabilitation facilities – medication-supported rehab,Contract rehabilitation and ancillary services, |
| BIOGEN | United States | Public Company | Multiple sclerosis portfolio (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS economics),SPINRAZA and rare neuromuscular (SPINRAZA, SKYCLARYS, QALSODY, zorevunersen pipeline),Alzheimer’s and psychiatry (LEQEMBI, ZURZUVAE), |
| CELGENE CORPORATION | United States | Private Company | REVLIMID (lenalidomide),POMALYST / THALOMID (immunomodulatory agents),REBLOZYL and hematology biologics, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing platforms, single-use, filtration, chromatography, aseptic fill-finish),Life Sciences (research instruments, genomics, mass spectrometry, microscopy, lab automation),Diagnostics (clinical instruments, consumables, software, services), |
| VERICEL CORPORATION | United States | Public Company | MACI (autologous cultured chondrocytes for knee cartilage repair),Epicel (permanent skin replacement for severe burns),NexoBrid (enzymatic eschar removal for thermal burns), |
| MESOBLAST | Australia | Public Company | Remestemcel-L (systemic inflammatory indications, including SR-aGVHD and IBD),Remestemcel-L (cardiac and chronic low back pain indications),MPC-300-IV and other MPC pipeline assets, |
| JCR PHARMACEUTICALS CO., LTD. | Japan | Public Company | Rare disease biologics (IZCARGO, Agalsidase Beta BS, others),Regenerative medicine / cell therapy (TEMCELL HS Inj),Endocrine / growth hormone (GROWJECT), |
| MEDIPOST | South Korea | Public Company | Cord Blood Bank (CELLTREE),Stem Cell Therapy (CARTISTEM and pipeline),Health Functional Food (MOVITA), |
| SMITH+NEPHEW | United Kingdom | Public Company | Orthopaedics (Knee, Hip, Trauma & Extremities, Other Reconstruction),Sports Medicine & ENT (Joint Repair, Arthroscopic Enabling Technologies, ENT Solutions),Advanced Wound Management (Advanced Wound Care, Bioactives, Devices), |
| ANTEROGEN CO., LTD. | South Korea | Public Company | Cell therapy pharmaceuticals (Cupistem, Remodulin-related business),Stem cell-based cosmetics (Queencell, Therastem lines, SCM2 hair care),Stem cell banking services, |
| CORESTEMCHEMON INC. | South Korea | Public Company | NEURONATA-R (ALS autologous BM-MSC therapy),Pipeline therapies (SLE, MSA, cerebellar ataxia),Non-clinical and precision solutions via ATG Lifetech partnership, |
| VERTEX PHARMACEUTICALS INCORPORATED | United States | Public Company | TRIKAFTA/KAFTRIO,Legacy CF modulators (ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO),Emerging pipeline and new launches (CASGEVY, JOURNAVX, others), |
| PHARMICELL CO., LTD | South Korea | Public Company | Biochemical Business (nucleosides, mPEGs, catalysts, low dielectric materials, flame retardants),Commercial Cell Therapy (Cellgram_AMI and related services),Pipeline Cell Therapies (Cellgram_LC, Cellgram_ED, Hearticellgram_AMI), |
| CIPLA LIMITED | India | Public Company | Branded generics (cardio-metabolism, respiratory, CNS, chronic),Unbranded generics and formulations (US and tender-driven),HIV/AIDS, infectious disease, and critical care, |
| BAYER AG | Germany | Public Company | Crop Science,Pharmaceuticals,Consumer Health, |
Kindred Healthcare Inc. is a United States-based private company founded in 1985 that operates with 64,200 employees. The company provides healthcare services and related solutions.
Biogen is a publicly traded United States biotechnology company founded in 1978 with 7,500 employees. The company focuses on drug discovery, development, and commercialization.
Celgene Corporation is a United States-based private pharmaceutical company founded in 1986 with 8,852 employees. The company develops and commercializes innovative medicines.
Danaher Corporation is a publicly traded United States conglomerate founded in 1969 with 59,000 employees. The company operates across multiple industrial and life sciences segments.
Vericel Corporation is a publicly traded United States company founded in 1989 with 398 employees. The company specializes in regenerative medicine and cell therapy products.
Mesoblast is an Australian publicly traded company founded in 2004 with 81 employees. The company focuses on cell therapy and regenerative medicine development.
JCR Pharmaceuticals Co., Ltd. is a publicly traded Japanese pharmaceutical company founded in 1975 with 985 employees. The company develops and commercializes pharmaceutical products.
Medipost is a South Korean publicly traded company founded in 2000 with 322 employees. The company operates in the biotechnology and regenerative medicine sector.
Smith+Nephew is a publicly traded United Kingdom-based medical devices company founded in 1856 with 16,988 employees. The company develops and markets orthopedic, wound care, and sports medicine products.
Anterogen Co., Ltd. is a South Korean publicly traded company founded in 2000. The company operates in the regenerative medicine and biotechnology sector.
CoreStemChemon Inc. is a South Korean publicly traded company founded in 2003 with 36 employees. The company focuses on stem cell and regenerative medicine research.
Vertex Pharmaceuticals Incorporated is a publicly traded United States biopharmaceutical company founded in 1989 with 6,400 employees. The company discovers, develops, and commercializes innovative medicines.
Pharmicell Co., Ltd is a South Korean publicly traded pharmaceutical company founded in 1968. The company develops and manufactures pharmaceutical and cell therapy products.
Cipla Limited is a publicly traded Indian pharmaceutical company founded in 1935 with 31,369 employees. The company develops, manufactures, and markets a broad range of pharmaceutical products.
Bayer AG is a publicly traded German multinational company founded in 1863 with 87,757 employees. The company operates across pharmaceuticals, consumer health, crop science, and other divisions.
The UK stem cell therapy market is valued at $0.4 million in 2026 and is projected to grow to $136.8 million by 2031.
Growth in the UK is driven by advanced regulatory frameworks, substantial research funding, NHS support, increasing clinical applications, and strong academic institutions specializing in regenerative medicine.
The UK's robust healthcare infrastructure, favorable reimbursement policies, and world-leading research institutions position it as a competitive hub for stem cell therapy innovation within Europe.
The UK market is expanding across multiple therapeutic areas including orthopedic disorders, neurological conditions, cardiovascular disease, and hematologic malignancies, with increasing clinical trial activity.
Stem cell therapies in the UK must navigate MHRA approval processes and comply with ATMP (Advanced Therapy Medicinal Product) regulations, with the UK maintaining rigorous standards post-Brexit.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global stem cell therapy market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size.
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and International Society for Cell & Gene Therapy (ISCT). Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global stem cell therapy market, and the findings were validated through primary research.
Following an initial assessment of the global stem cell therapy market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were conducted with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% were conducted with demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to comprehensively understand market dynamics.
The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure
Both bottom-up and top-down approaches were used to estimate and validate the total size of the global stem cell therapy market. These methods were also widely used to estimate the sizes of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
The stem cell therapy market encompasses approved and commercialized stem cell-based therapeutic products, pipeline therapies, and associated clinical services used for regenerative and reparative treatment of diseases and conditions. This market includes various cell source types (adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, induced pluripotent stem cells, embryonic stem cells, tissue-specific stem cells, and other cell sources), therapy types (allogeneic and autologous), and therapeutic applications spanning musculoskeletal disorders, wounds & surgeries, inflammatory & autoimmune diseases, cardiovascular diseases, neurological disorders, diabetes & metabolic diseases, and other conditions. It serves end users, including hospitals, specialty/stem cell clinics, ambulatory surgical centers, academic & research institutes, and cell & tissue banks.
With the given market data, MarketsandMarkets offers customizations to meet your company's needs. The following customization options are available for this report:
Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies
Detailed analysis and profiling of additional market players (up to three)
Full forecast, segment splits, and company analysis for all Stem Cell Therapy Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report